IP Library › Granted Patent US 12,303,134
Granted Patent B2
US 12,303,134 · App. 17/131,447 · Granted May 20, 2025

Systems for aneurysm treatment

Inventors: Eric Wells (Mesa, AZ); Kelvin Ning (Scottsdale, AZ)
Assignee: Nectero Medical, Inc
A61B17/12113A61B17/12136A61K31/7032A61K47/10A61K47/20A61L29/16A61M25/1011C07H1/06C07H13/08A61L2300/232A61M2025/105A61M2025/1052A61M2025/1086A61M2205/0238
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,134
App. No.
17/131,447
Granted
May 20, 2025
Kind
B2
Abstract

Disclosed herein is a method of producing high purity pentagalloyl glucose (PGG), analogues or derivatives thereof, at least 99.9% pure, by washing with dimethyl ether. The PGG may be provided in a kit, including a hydrolyzer for dissolving the PGG and a saline solution. Also disclosed herein is a device for delivery of a therapeutic solution to a blood vessel. The device may be a catheter having an upstream balloon and a downstream balloon. The upstream balloon may be expanded to anchor the catheter and occlude antegrade blood flow. The downstream balloon may be expanded to occlude retrograde blood flow, creating a sealed volume within the blood vessel. The downstream balloon may have pores configured to deliver the therapeutic solution into the sealed volume or a portion of the sealed volume. The downstream balloon may be expanded by an expansion of a balloon disposed inside the downstream balloon.

Claims (49)

1. A device for treating an aneurysm, the device comprising:

a shaft;

a first balloon attached to a distal end of the shaft,

wherein the first balloon is configured to anchor the device and to occlude downstream blood flow upon expansion of the first balloon; and

a second balloon attached proximal of the first balloon,

wherein the second balloon is configured to be substantially aligned with the aneurysm,

wherein the second balloon is configured to displace blood from a sac of the aneurysm when the second balloon is expanded,

wherein the second balloon is formed of a material that is sufficiently compliant and conformable to assume a shape of the sac of the aneurysm,

wherein a maximum expanded diameter of the second balloon is greater than a maximum expanded diameter of the first balloon,

wherein the second balloon comprises a plurality of pores for delivering a therapeutic agent to the aneurysm,

wherein the plurality of pores of the second balloon are configured to place an interior volume of the second balloon in fluid communication with an intravascular environment of the aneurysm,

wherein the plurality of pores comprises between 30 and 200 pores and wherein a diameter of each of the plurality of pores is between 0.05 mm and 0.2 mm so as to deliver a fluid from the plurality of pores at a volumetric flow rate between 0.05 mL/min and 20 mL/min, and

wherein the volumetric flow rate is constant or substantially constant.

2. A kit for treating aneurysms, the kit comprising:

the device of claim 1 ;

purified pentagalloyl glucose (PGG); and

a hydrolyzer.

3. The device of claim 1 , wherein the first balloon comprises a generally spherical shape and the second balloon comprises a generally prolate spheroid shape.

4. The device of claim 1 , further comprising a handle, wherein the handle comprises a first port and a second port, wherein the first port is configured to allow a first fluid to be introduced to cause the expansion of the first balloon, wherein the second port is configured to allow a second fluid to be introduced to cause the expansion of the second balloon, and wherein the second port is configured to allow the therapeutic agent to be introduced and delivered through the plurality of pores of the second balloon.

5. The device of claim 4 , wherein the maximum expanded diameter of the second balloon is between 125% and 175% of the maximum expanded diameter of the first balloon, wherein a length of the second balloon is greater than a length of the first balloon, and wherein, upon a maximum expansion of the second balloon, the length of the second balloon is greater than the maximum expanded diameter of the second balloon.

6. The device of claim 1 , wherein the plurality of pores comprises 40 pores.

7. The device of claim 1 , wherein the volumetric flow rate is 8 mL/min.

8. A catheter for treating an aneurysm, the catheter comprising:

an elongate body configured to be introduced into a blood vessel, the elongate body having a proximal end, a distal end, and a main shaft having a lumen extending therethrough;

a first inflatable balloon coupled to the distal end of the elongate body, the first inflatable balloon having an interior volume in fluid communication with a first inflation lumen and being configured to occlude downstream blood flow upon expansion; and

a second inflatable balloon coupled to the elongate body proximally to the first inflatable balloon, the second inflatable balloon having an interior volume in fluid communication with a second inflation lumen,

wherein the second inflatable balloon is configured to be substantially aligned with the aneurysm,

wherein the second inflatable balloon is formed of a material that is sufficiently compliant and conformable to assume a shape of a sac of the aneurysm when the second inflatable balloon is expanded,

wherein a maximum expanded diameter of the second inflatable balloon is greater than a maximum expanded diameter of the first inflatable balloon,

wherein the second inflatable balloon circumferentially surrounds the elongate body,

wherein the second inflatable balloon comprises a plurality of pores disposed on a surface of the second inflatable balloon configured to place the interior volume of the second inflatable balloon in fluid communication with an intravascular environment of the blood vessel,

wherein the plurality of pores comprises between 30 and 200 pores and wherein a diameter of each of the plurality of pores is between 0.05 mm and 0.2 mm so as to deliver a fluid from the plurality of pores at a volumetric flow rate between 0.05 mL/min and 20 mL/min.

9. The catheter of claim 8 , wherein the main shaft extends through the second inflatable balloon and a distal end of the main shaft forms the distal end of the elongate body.

10. The catheter of claim 9 , wherein the first inflation lumen and the second inflation lumen are formed within the main shaft.

11. The catheter of claim 8 , wherein the elongate body further comprises a second shaft having a lumen extending therethrough, the second shaft being disposed within the lumen of the main shaft, the first inflatable balloon being coupled to a distal end of the second shaft and the second inflatable balloon being coupled to a distal end of the main shaft.

12. The catheter of claim 11 , wherein the lumen of the main shaft is the second inflation lumen.

13. The catheter of claim 11 , wherein the lumen of the second shaft is the first inflation lumen.

14. The catheter of claim 11 , wherein the second inflatable balloon is generally a prolate spheroid shape forming an annular interior volume that surrounds the elongate body.

15. The catheter of claim 11 , wherein the maximum expanded diameter of the second inflatable balloon is approximately 175% of the maximum expanded diameter of the first inflatable balloon, wherein, upon the expansion of the second inflatable balloon, a length of the second inflatable balloon is greater than a length of the first inflatable balloon, and wherein, upon the expansion of the second inflatable balloon expanded second inflatable balloon.

16. The catheter of claim 11 , further comprising a third inflatable balloon disposed within the interior volume of the second inflatable balloon, the third inflatable balloon having an interior volume in fluid communication with a third inflation lumen, wherein an expansion of the third inflatable balloon is configured to at least partially expand the second inflatable balloon, and wherein the expansion of the third inflatable balloon is configured to facilitate expulsion of at least a partial volume of inflation fluid disposed within the interior volume of the second inflatable balloon through the plurality of pores into the intravascular environment.

17. The catheter of claim 8 , wherein the second inflatable balloon comprises a membrane that is less compliant than a membrane of the first inflatable balloon.

18. The catheter of claim 8 , wherein the first inflatable balloon comprises a generally spherical shape and the second inflatable balloon comprises a generally prolate spheroid shape.

19. The catheter of claim 8 , wherein a separation distance between the first inflatable balloon and the second inflatable balloon is fixed.

20. The catheter of claim 8 , further comprising a handle, wherein the handle comprises a first port and a second port, wherein the first port is configured to allow a first fluid to be introduced into the first inflation lumen to cause the expansion of the first inflatable balloon, wherein the second port is configured to allow a second fluid to be introduced into the second inflation lumen to cause an expansion of the second inflatable balloon, and wherein the second port is configured to allow a therapeutic agent to be introduced into the second inflation lumen to be delivered through the plurality of pores of the second inflatable balloon.

21. The catheter of claim 20 , wherein the maximum expanded diameter of the second inflatable balloon is between 125% and 175% of the maximum expanded diameter of the first inflatable balloon, wherein a length of the second inflatable balloon is greater than a length of the first inflatable balloon, and wherein, upon a maximum expansion of the second inflatable balloon, the length of the second inflatable balloon is greater than the maximum expanded diameter of the second inflatable balloon.

22. The catheter of claim 8 , wherein the diameter of each of the plurality of pores is the same when the second inflatable balloon is in a maximum expanded configuration as when the second inflatable balloon is not expanded.

23. The catheter of claim 8 , wherein the volumetric flow rate is constant or substantially constant.

24. The catheter of claim 23 , wherein the volumetric flow rate is 8 mL/min.

25. The catheter of claim 8 , wherein the plurality of pores comprises 40 pores.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: WELLS, ERIC; NING, KELVIN
To: NECTERO MEDICAL, INC.
Reel/Frame 055244/0880 →
Continuity (3)
Continuation PCTUS2019024140 · Mar 26, 2019
Provisional Application 62714346 · Aug 3, 2018
Related Publication 20210106339A1 · Apr 15, 2021
References Cited (166)
US 4404971A · LeVeen et al. · 1983 [cited by applicant]
US 4423725A · Baran et al. · 1984 [cited by applicant]
US 4577631A · Kreamer · 1986 [cited by applicant]
US 4741915A · Farr · 1988 [cited by applicant]
US 5041090A · Scheglov et al. · 1991 [cited by applicant]
US 5405322A · Lennox et al. · 1995 [cited by applicant]
US 5489295A · Piplani et al. · 1996 [cited by applicant]
US 5611775A · Machold et al. · 1997 [cited by applicant]
US 5857998A · Barry · 1999 [cited by applicant]
US 5868776A · Wright · 1999 [cited by applicant]
US 5919163A · Glickman · 1999 [cited by examiner]
US 6048332A · Duffy et al. · 2000 [cited by applicant]
US 6575932B1 · O'Brien et al. · 2003 [cited by applicant]
US 6706013B1 · Bhat et al. · 2004 [cited by applicant]
US 7252834B2 · Vyavahare · 2007 [cited by applicant]
US 7314484B2 · Deem et al. · 2008 [cited by applicant]
US 7323169B2 · Goldenberg · 2008 [cited by applicant]
US 7713543B2 · Vyavahare · 2010 [cited by applicant]
US 7732399B2 · Goldenberg · 2010 [cited by applicant]
US 7772381B2 · Himmeldirk · 2010 [cited by applicant]
US 8034022B2 · Boatman · 2011 [cited by applicant]
US 8100961B2 · Vyavahare · 2012 [cited by applicant]
US 8142805B1 · Vyavahare · 2012 [cited by applicant]
US 8317747B2 · Kusleika · 2012 [cited by applicant]
US 8357796B2 · Ren et al. · 2013 [cited by applicant]
US 8435553B2 · Vyavahare · 2013 [cited by applicant]
US 8444624B2 · Ogle et al. · 2013 [cited by applicant]
US 8496911B2 · Weldon et al. · 2013 [cited by applicant]
US 8591461B2 · Boatman · 2013 [cited by applicant]
US 8642578B2 · Mitts · 2014 [cited by applicant]
US 8827953B2 · Rochal-Singh · 2014 [cited by applicant]
US 8911468B2 · Ogle et al. · 2014 [cited by applicant]
US 9044570B2 · Weldon · 2015 [cited by applicant]
US 9181290B2 · Liu et al. · 2015 [cited by applicant]
US 9277923B2 · Rangi · 2016 [cited by applicant]
US 9283241B2 · Simonescu · 2016 [cited by applicant]
US 9370644B2 · Rocha-Singh · 2016 [cited by applicant]
US 9795573B2 · Vyavahare · 2017 [cited by applicant]
US 9889279B2 · Ogle et al. · 2018 [cited by applicant]
US 9907818B2 · Huang et al. · 2018 [cited by applicant]
US 9937255B2 · Ogle et al. · 2018 [cited by applicant]
US 11007351B2 · Bacino et al. · 2021 [cited by applicant]
US 11331102B2 · Wells et al. · 2022 [cited by applicant]
US 20010016724A1 · Davis et al. · 2001 [cited by applicant]
US 20010041862A1 · Glickman · 2001 [cited by applicant]
US 20020115982A1 · Barbut et al. · 2002 [cited by applicant]
US 20030036728A1 · Samson et al. · 2003 [cited by applicant]
US 20040153025A1 · Seifert et al. · 2004 [cited by applicant]
US 20040153120A1 · Seifert et al. · 2004 [cited by applicant]
US 20040153145A1 · Simonescu · 2004 [cited by applicant]
US 20050027247A1 · Carrison · 2005 [cited by examiner]
US 20050085685A1 · Barbut · 2005 [cited by applicant]
US 20050158272A1 · Whirley · 2005 [cited by applicant]
US 20060079923A1 · Chhabra et al. · 2006 [cited by applicant]
US 20070150041A1 · Evans et al. · 2007 [cited by applicant]
US 20070259030A1 · Drapeau · 2007 [cited by applicant]
US 20070281026A1 · Vyavahare et al. · 2007 [cited by applicant]
US 20070282422A1 · Biggs · 2007 [cited by examiner]
US 20070293937A1 · Biggs et al. · 2007 [cited by applicant]
US 20080208163A1 · Wilkie · 2008 [cited by applicant]
US 20080249299A1 · Ren · 2008 [cited by examiner]
US 20090155337A1 · Schreck · 2009 [cited by applicant]
US 20090186370A1 · Ogle et al. · 2009 [cited by applicant]
US 20090198266A1 · Cesare · 2009 [cited by examiner]
US 20090203150A1 · Chen · 2009 [cited by applicant]
US 20090214654A1 · Isenberg · 2009 [cited by applicant]
US 20090254064A1 · Boatman · 2009 [cited by examiner]
US 20090270964A1 · Huetter et al. · 2009 [cited by applicant]
US 20100016833A1 · Ogle · 2010 [cited by applicant]
US 20100119605A1 · Isenburg · 2010 [cited by applicant]
US 20100261662A1 · Schreck · 2010 [cited by applicant]
US 20110081423A1 · Weldon et al. · 2011 [cited by applicant]
US 20110093000A1 · Ogle et al. · 2011 [cited by applicant]
US 20110104233A1 · Drapeau · 2011 [cited by applicant]
US 20110125132A1 · Krolik · 2011 [cited by examiner]
US 20110218517A1 · Ogle et al. · 2011 [cited by applicant]
US 20120015019A1 · Pacetti et al. · 2012 [cited by applicant]
US 20120143054A1 · Eaton et al. · 2012 [cited by applicant]
US 20120184982A1 · Herbowy et al. · 2012 [cited by applicant]
US 20120316436A1 · Lentz · 2012 [cited by examiner]
US 20120321566A1 · Liu et al. · 2012 [cited by applicant]
US 20120323211A1 · Ogle · 2012 [cited by examiner]
US 20140017263A1 · Vyavahare · 2014 [cited by applicant]
US 20140039459A1 · Folk et al. · 2014 [cited by applicant]
US 20140200504A1 · Rocha-Singh · 2014 [cited by applicant]
US 20140243873A1 · Franklin · 2014 [cited by applicant]
US 20150005744A1 · Ogle et al. · 2015 [cited by applicant]
US 20150087611A1 · Vyavahare et al. · 2015 [cited by applicant]
US 20150190619A1 · Rocha-Singh · 2015 [cited by applicant]
US 20160082178A1 · Agah · 2016 [cited by examiner]
US 20160136109A1 · Isenburg et al. · 2016 [cited by applicant]
US 20160339212A1 · Bacino et al. · 2016 [cited by applicant]
US 20160348068A1 · Hagay et al. · 2016 [cited by applicant]
US 20170007584A1 · Yeritsyan · 2017 [cited by applicant]
US 20170209592A1 · Vyavahare · 2017 [cited by applicant]
US 20170258613A1 · Franano et al. · 2017 [cited by applicant]
US 20170281140A1 · Arahira et al. · 2017 [cited by applicant]
US 20170340434A1 · Cerchiari et al. · 2017 [cited by applicant]
US 20170354523A1 · Chou et al. · 2017 [cited by applicant]
US 20180036261A1 · Vyavahare et al. · 2018 [cited by applicant]
US 20180064565A1 · MacTaggart et al. · 2018 [cited by applicant]
US 20180214469A1 · Chen et al. · 2018 [cited by applicant]
US 20180326071A1 · Ogle et al. · 2018 [cited by applicant]
US 20180338766A1 · Ogle et al. · 2018 [cited by applicant]
US 20180344665A1 · Isenburg et al. · 2018 [cited by applicant]
US 20180344990A1 · Ogle et al. · 2018 [cited by applicant]
US 20190070026A1 · Fulton · 2019 [cited by examiner]
US 20190117242A1 · Lawinger et al. · 2019 [cited by applicant]
US 20210147462A1 · Wells et al. · 2021 [cited by applicant]
US 20210308433A1 · Gifford, III et al. · 2021 [cited by applicant]
US 20220000896A1 · Ning · 2022 [cited by applicant]
US 20220000897A1 · Ning · 2022 [cited by applicant]
US 20230233209A1 · Wells et al. · 2023 [cited by applicant]
US 20230233210A1 · Murphy · 2023 [cited by applicant]
US 20230310475A1 · Ning · 2023 [cited by applicant]
CN 200951251 · 2007 [cited by applicant]
CN 101480407 · 2009 [cited by applicant]
CN 101525357 · 2009 [cited by applicant]
CN 101926394 · 2010 [cited by applicant]
CN 102698354 · 2012 [cited by applicant]
CN 102887924 · 2013 [cited by applicant]
CN 203852722U · 2014 [cited by applicant]
CN 106699819 · 2017 [cited by applicant]
CN 106905480 · 2017 [cited by applicant]
CN 107550534A · 2018 [cited by applicant]
DE 10302241 · 2004 [cited by applicant]
EP 2508221A1 · 2012 [cited by applicant]
JP 2001511022 · 2001 [cited by applicant]
JP 2008007468 · 2008 [cited by applicant]
JP 2011528254 · 2011 [cited by applicant]
JP 2017176385 · 2017 [cited by applicant]
WO WO1987005297 · 1987 [cited by applicant]
WO WO9809670 · 1998 [cited by applicant]
WO WO0018416 · 2000 [cited by applicant]
WO WO2001070325A2 · 2001 [cited by applicant]
WO WO2008123937A1 · 2008 [cited by applicant]
WO WO2009105265A2 · 2009 [cited by applicant]
WO WO2010008513 · 2010 [cited by applicant]
WO WO2012158944A1 · 2012 [cited by applicant]
WO WO2016044647 · 2016 [cited by applicant]
WO WO2016079330 · 2016 [cited by applicant]
WO WO2020027882 · 2020 [cited by applicant]
Kloster et al., Inhibition of Early AAA Formation by Aortic Intraluminal Pentagalloyl Glucose (PGG) Infusion in a Novel Porcine AAA Model, Annals of Medicine and Surgery, vol. 7, pp. 65-70, May 1, 2016. [cited by applicant]
Isenburg et al., Elastin Stabilization for Treatment of Abdominal Aortic Aneurysms, Circulation, vol. 114, pp. 1729-1737, Mar. 2007. [cited by applicant]
Zhang et al., Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose, Pharm Res., vol. 26(9), Sep. 2009. [cited by applicant]
Torres-Leon et al., Pentagalloylglucose (PGG): A valuable phenolic compound with functional properties, Journal of Functional Foods, vol. 37, pp. 176-189, Oct. 2017. [cited by applicant]
Chen et al., Preparation of 1,2,3,4,6-penta-O-galloyl-[U- [cited by applicant]
International Search Report and Written Opinion; Int'l Application No. PCT/US2019/24142; dated Jul. 19, 2019. [cited by applicant]
International Search Report and Written Opinion; Int'l Application No. PCT/US19/24140; dated Jun. 21, 2019, 24 pages. [cited by applicant]
Glossary od Medical Education Terms, Institute of International Medical Education, 2013, https://web.archive.org/web/20130514003055/hhtp://www.lime.org/glossary.htm, Accessed on Dec. 1, 2021. [cited by applicant]
Nosoudi et al., “Reversal of Vascular Calcification and Aneurysms in a Rat Model UsingDual Targeted Therapy with EDTA and PGG-Loaded Nanoparticles,” Theranostics, 2016, 6(11), pp. 1975-1987. [cited by applicant]
Li et al., “Preparation of penta-O-galloyl-βb-d-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC”, J Pharma Biomed Anal. Feb. 20, 2011; 54(3): 545-550. [cited by applicant]
Chen et al., “Characterization of soluble non-covalent complexes between bovine serum albumin and beta-1,2,3,4,6-penta-O-galloyl-D-glucopyranose by MALDI-TOF MS”, J Agricult Food Chem. Jun. 16, 2004; 52(12): 4008-4011. [cited by applicant]
Extended European Search Report dated Apr. 4, 2022, for Application No. 19845328.4 in 8 pages. [cited by applicant]
Extended European Search Report dated May 30, 2022, for Application No. 19844863.1 in 12 pages. [cited by applicant]
Allen et al. [Eds.], Ansel's Introduction to Pharmaceutical Dosage Forms and Drug Delivery Systems; 8th Edition (2004); Book Cover. [cited by applicant]
Banker et al., [Eds.] Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (2002) in 98 pages. [cited by applicant]
Gilman et al. (Eds.) Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press (1990) TOC in 8 pages. [cited by applicant]
Lieberman et al. [Eds.], Pharmaceutical Dosage Forms: Tablets (1989); TOC in 7 pages. [cited by applicant]
Nema et al., “Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions”. PDA J Pharm Sci and Tech. May 1, 2011;65(3): 287-332. [cited by applicant]
Powell et al., “Compendium of Excipients for Parenteral Formulations”. PDA J Pharm Sci and Tech. Sep. 1, 1998;52(5): 238-311. [cited by applicant]
Remington's The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (2005), TOC in 4 pages. [cited by applicant]
Zhao et al., “Research Progress of Hydrolyzed Tannin PGG as a Traditional Chinese Medicine”. J Clin Exp Med. Mar. 2013;12(6): 462-464. [cited by applicant]
Research Progress of hydrolyzed Tannin PGG as a Traditional Chinese Medicine, Yong Zhao, et al., Journal of Clinical and Experimental Medicine, vol. 12, No. 6. pp. 462-464. [cited by applicant]
Shaffer, C. Dr., “What is Elastin?”, News Medical (online); 2019; downloaded from URL https://www.news-medical.net/life-sciences/What-is-Elastin.aspx; on Apr. 22, 22; 4 pages. (year 2019). [cited by applicant]
Ahldén et al., “Knee laxity measurements after anterior cruciate ligament reconstruction, using either bone-patellar-tendon-bone or hamstring tendon autografts, with special emphasis on comparison over time.” Knee Surg … [cited by applicant]